RCUS

Arcus BiosciencesB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$36.00

+47.1% vs current

Most likely

Base case

45%

Probability

Target price

$28.00

+14.4% vs current

B-

Bear case

30%

Probability

Target price

$17.00

-30.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This remains a cautious monitoring setup. The key new evidence on May 5, 2026 came from company materials rather than broad analyst digestion: the earnings release and 8-K confirmed a stronger runway and a clearer casdatifan-first plan, but also a narrower portfolio after STAR-121. Immediate market reaction appears muted rather than thesis-changing, and by May 8, 2026 visible post-print analyst revision evidence was still thin, so confidence should stay moderate rather than bullishly upgraded. [#8-K-2026-05-05][#10-Q-2026-05-05]

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-05catalystQ1 earnings reset preserved runway but confirmed a narrower, casdatifan-led storyMedium impact

The May 5, 2026 earnings release confirmed $876 million of cash and marketable securities, runway into at least the second half of 2028, expected R&D relief from winding down domvanalimab studies, and a sharper capital focus on casdatifan. That reduces near-term financing risk, but it does not by itself create a new upside leg without later clinical proof. [#8-K-2026-05-05][#10-Q-2026-05-05]

2026-09-30eventMultiple 2026 casdatifan readouts now carry most of the rerating burdenHigh impact

Arcus guided to 2026 data from ARC-20, including more mature overall response and initial progression-free-survival data for casdatifan plus cabozantinib in IO-experienced ccRCC, initial early-line cohort data, and updated late-line monotherapy results. With domvanalimab de-emphasized after STAR-121 was stopped for futility, these readouts are now the main stock-moving proof points. [#8-K-2026-05-05]

2026-12-31catalystPEAK-1 enrollment completion and a first-line Phase 3 start by year-end would strengthen the RCC backbone thesisHigh impact

Management said PEAK-1 enrollment is accelerating and that both PEAK-1 enrollment completion and initiation of a first-line Phase 3 study are expected by year-end 2026. Hitting those milestones would show execution against the post-TIGIT reset plan, but failure would reinforce that the investment case is overly concentrated in one franchise. [#8-K-2026-05-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology